Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

類似資料

• Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
  著者:: Sieper, J, 等
  出版事項: (2015)
• Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
  著者:: van der Heijde, D., 等
  出版事項: (2017)
• A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  著者:: Deodhar, Atul, 等
  出版事項: (2019)
• Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
  著者:: Landewé, Robert BM, 等
  出版事項: (2020)
• The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
  著者:: van der Horst-Bruinsma, Irene, 等
  出版事項: (2020)